Establishment of a Novel Risk Score System of Immune Genes Associated With Prognosis in Esophageal Carcinoma.
bioinformatics
esophageal carcinoma
histological subtype
immune gene
immunotherapy
prognostic model index
risk score
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
11
2020
accepted:
15
03
2021
entrez:
16
4
2021
pubmed:
17
4
2021
medline:
17
4
2021
Statut:
epublish
Résumé
Few studies have addressed the role of immune-related genes in the survival and prognosis of different esophageal cancer (EC) sub-types. We established two new prognostic model indexes by bioinformatics analysis to select patients with esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) who may benefit from immunotherapy. Based on TCGA and ImmPort data sets, we screened immune genes differentially expressed between tumor and normal tissues in ESCC and EAC and analyzed the relationship between these genes and patient survival outcomes. We established the risk score models of immune-related genes in ESCC and EAC by multivariate COX regression analysis. We identified 12 and 11 immune-related differentially expressed genes associated with the clinical prognosis of ESCC and EAC respectively, based on which two prognostic risk score models of the two EC sub-types were constructed. It was found that the survival probability of patients with high scores was significantly lower than that of patients with low scores (p < 0.001). BMP1, EGFR, S100A12, HLA-B, TNFSF18, IL1B, MAPT and OXTR were significantly related to sex, TNM stage or survival outcomes of ESCC or EAC patients (p < 0.05). In addition, the risk score of ESCC was significantly correlated with the level of B cell infiltration in immune cells (p < 0.05). The prognosis-related immune gene model indexes described herein prove to be useful prognostic biomarkers of the two EC sub-types in that they may provide a reference direction for looking for the beneficiaries of immunotherapy for EC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Few studies have addressed the role of immune-related genes in the survival and prognosis of different esophageal cancer (EC) sub-types. We established two new prognostic model indexes by bioinformatics analysis to select patients with esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) who may benefit from immunotherapy.
METHODS
METHODS
Based on TCGA and ImmPort data sets, we screened immune genes differentially expressed between tumor and normal tissues in ESCC and EAC and analyzed the relationship between these genes and patient survival outcomes. We established the risk score models of immune-related genes in ESCC and EAC by multivariate COX regression analysis.
RESULTS
RESULTS
We identified 12 and 11 immune-related differentially expressed genes associated with the clinical prognosis of ESCC and EAC respectively, based on which two prognostic risk score models of the two EC sub-types were constructed. It was found that the survival probability of patients with high scores was significantly lower than that of patients with low scores (p < 0.001). BMP1, EGFR, S100A12, HLA-B, TNFSF18, IL1B, MAPT and OXTR were significantly related to sex, TNM stage or survival outcomes of ESCC or EAC patients (p < 0.05). In addition, the risk score of ESCC was significantly correlated with the level of B cell infiltration in immune cells (p < 0.05).
CONCLUSIONS
CONCLUSIONS
The prognosis-related immune gene model indexes described herein prove to be useful prognostic biomarkers of the two EC sub-types in that they may provide a reference direction for looking for the beneficiaries of immunotherapy for EC patients.
Identifiants
pubmed: 33859939
doi: 10.3389/fonc.2021.625271
pmc: PMC8042266
doi:
Types de publication
Journal Article
Langues
eng
Pagination
625271Informations de copyright
Copyright © 2021 Fei, Xie, Chen, Xie, Gu, Zhou and Xu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Sci. 2020 Sep;111(9):3132-3141
pubmed: 32579769
Lancet. 2017 Nov 25;390(10110):2383-2396
pubmed: 28648400
Clin Cancer Res. 2019 Oct 15;25(20):6160-6169
pubmed: 31337644
Front Oncol. 2020 Mar 05;10:300
pubmed: 32195194
J Clin Oncol. 2020 Dec 10;38(35):4138-4148
pubmed: 33026938
Surg Oncol. 2017 Sep;26(3):278-285
pubmed: 28807247
Aging (Albany NY). 2019 Jan 20;11(2):480-500
pubmed: 30661062
Int Immunopharmacol. 2020 Oct;87:106795
pubmed: 32707495
Front Genet. 2020 Aug 21;11:989
pubmed: 32973887
Oncotarget. 2016 Sep 27;7(39):63526-63536
pubmed: 27556859
J Cell Physiol. 2020 Dec;235(12):9834-9850
pubmed: 32452055
Nature. 2017 Jan 12;541(7636):169-175
pubmed: 28052061
BMC Cancer. 2018 May 2;18(1):508
pubmed: 29720137
Cell Biosci. 2018 Feb 5;8:7
pubmed: 29441192
Lancet Oncol. 2017 May;18(5):631-639
pubmed: 28314688
JAMA Oncol. 2019 Apr 1;5(4):546-550
pubmed: 30570649
Int J Mol Sci. 2017 Mar 16;18(3):
pubmed: 28300755
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Thorac Oncol. 2017 Jun;12(6):1001-1010
pubmed: 28351804
Gastroenterology. 2018 Jan;154(2):360-373
pubmed: 28823862
Int J Oncol. 2020 Apr;56(4):945-956
pubmed: 32319582
Oncologist. 2015 Oct;20(10):1132-9
pubmed: 26336083
Lancet Oncol. 2019 Nov;20(11):1506-1517
pubmed: 31582355
Carcinogenesis. 2020 Sep 17;:
pubmed: 32940666
Aging (Albany NY). 2020 Mar 31;12(7):5832-5857
pubmed: 32235004
J Clin Oncol. 2018 Jan 1;36(1):61-67
pubmed: 29116900
Mol Cancer. 2020 May 2;19(1):81
pubmed: 32359357
Oncol Rep. 2019 Feb;41(2):1359-1366
pubmed: 30535461
Mol Cancer. 2018 Feb 19;17(1):54
pubmed: 29455652
Gut. 2018 Oct;67(10):1769-1779
pubmed: 28860350
Clin Cancer Res. 2020 Sep 15;26(18):4921-4932
pubmed: 32646922
Front Oncol. 2020 Jul 24;10:1211
pubmed: 32850356
Cell Res. 2020 Oct;30(10):902-913
pubmed: 32398863
Int Immunopharmacol. 2019 Nov;76:105869
pubmed: 31499272
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Front Oncol. 2019 Sep 27;9:996
pubmed: 31612115
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369
pubmed: 30545915
Ann Transl Med. 2020 Mar;8(6):284
pubmed: 32355728
Cancer Immunol Immunother. 2020 Aug;69(8):1493-1504
pubmed: 32285170
J Cell Physiol. 2021 Apr;236(4):2572-2591
pubmed: 32853412
Gastroenterology. 2018 Jan;154(2):390-405
pubmed: 28780073
Transl Oncol. 2018 Dec;11(6):1323-1333
pubmed: 30172884
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncoimmunology. 2017 Jul 31;6(11):e1356147
pubmed: 29147607
Cancer Sci. 2017 Apr;108(4):590-597
pubmed: 28192623
Signal Transduct Target Ther. 2020 Sep 4;5(1):182
pubmed: 32883946
Cancer Gene Ther. 2020 May;27(5):330-340
pubmed: 31155610
Front Oncol. 2020 Jul 24;10:1317
pubmed: 32850416